Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.

Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M.

Clin Cancer Res. 2013 Jun 1;19(11):2952-61. doi: 10.1158/1078-0432.CCR-13-0238. Epub 2013 Apr 15.

2.

Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.

Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, Edler D, Mkrtchian S, Ingelman-Sundberg M.

Mol Pharmacol. 2010 Dec;78(6):1004-11. doi: 10.1124/mol.110.067652. Epub 2010 Aug 30.

3.

Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors.

Choong E, Guo J, Persson A, Virding S, Johansson I, Mkrtchian S, Ingelman-Sundberg M.

PLoS One. 2015 Apr 6;10(4):e0122820. doi: 10.1371/journal.pone.0122820. eCollection 2015.

4.

The expression of CYP2W1: a prognostic marker in colon cancer.

Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D.

Anticancer Res. 2012 Sep;32(9):3869-74.

PMID:
22993331
5.

Expression of CYP2W1 in colon tumors: regulation by gene methylation.

Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M.

Pharmacogenomics. 2007 Oct;8(10):1315-25.

PMID:
17979506
6.

CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.

Stenstedt K, Travica S, Guo J, Barragan I, Pors K, Patterson L, Edler D, Mkrtchian S, Johansson I, Ingelman-Sundberg M.

Pharmacogenomics. 2013 Oct;14(13):1615-22. doi: 10.2217/pgs.13.136.

PMID:
24088132
7.

Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers.

Chung FF, Mai CW, Ng PY, Leong CO.

Curr Cancer Drug Targets. 2016;16(1):71-8. Review.

PMID:
26563883
8.

Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1.

Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, Bernal ML, Ramón y Cajal S, Johansson I, Ingelman-Sundberg M.

Biochem Biophys Res Commun. 2006 Mar 10;341(2):451-8. Epub 2006 Jan 11.

PMID:
16426568
9.

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K.

J Med Chem. 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26.

PMID:
23844629
10.

Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas.

Nolé P, Duijndam B, Stenman A, Juhlin CC, Kozyra M, Larsson C, Ingelman-Sundberg M, Johansson I.

PLoS One. 2016 Sep 6;11(9):e0162379. doi: 10.1371/journal.pone.0162379. eCollection 2016.

11.

The CYP2W1 enzyme: regulation, properties and activation of prodrugs.

Guo J, Johansson I, Mkrtchian S, Ingelman-Sundberg M.

Drug Metab Rev. 2016 Aug;48(3):369-78. doi: 10.1080/03602532.2016.1188939. Epub 2016 Jun 3. Review.

PMID:
27257736
12.

Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1.

Guo J, Thiess S, Johansson I, Mkrtchian S, Ingelman-Sundberg M.

FEBS Lett. 2016 Feb;590(3):330-9. doi: 10.1002/1873-3468.12063. Epub 2016 Feb 2.

13.

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH.

Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1.

14.

Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates.

Li W, Tang Y, Hoshino T, Neya S.

J Mol Graph Model. 2009 Sep;28(2):170-6. doi: 10.1016/j.jmgm.2009.06.002. Epub 2009 Jun 21.

PMID:
19596602
15.

CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.

Tan BS, Tiong KH, Muruhadas A, Randhawa N, Choo HL, Bradshaw TD, Stevens MF, Leong CO.

Mol Cancer Ther. 2011 Oct;10(10):1982-92. doi: 10.1158/1535-7163.MCT-11-0391. Epub 2011 Aug 10.

16.

The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study.

Edler D, Stenstedt K, Ohrling K, Hallström M, Karlgren M, Ingelman-Sundberg M, Ragnhammar P.

Eur J Cancer. 2009 Mar;45(4):705-12. doi: 10.1016/j.ejca.2008.11.031. Epub 2008 Dec 30.

PMID:
19118998
17.

Cytochrome P450 2W1 (CYP2W1) - ready for use as the biomarker and drug target for cancer?

Pan Y, Ong EC.

Xenobiotica. 2017 Oct;47(10):923-932. doi: 10.1080/00498254.2016.1244370. Epub 2016 Oct 24.

PMID:
27690753
18.

The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases.

Stenstedt K, Hallstrom M, Lédel F, Ragnhammar P, Ingelman-Sundberg M, Johansson I, Edler D.

Acta Oncol. 2014 Jul;53(7):885-91. doi: 10.3109/0284186X.2014.887224. Epub 2014 Mar 13.

PMID:
24625228
19.

Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy.

Karlgren M, Ingelman-Sundberg M.

Expert Opin Ther Targets. 2007 Jan;11(1):61-7. Review.

PMID:
17150034
20.

Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.

Clin Cancer Res. 2008 Apr 1;14(7):2180-9. doi: 10.1158/1078-0432.CCR-07-1392.

Supplemental Content

Support Center